Similar articles

• Atrial Fibrillation and Cancer-Validation in the Real World-Reply.

  Conen D, Albert CM. Conen D, et al. JAMA Cardiol. 2017 Mar 1;2(3):344. doi: 10.1001/jamacardio.2016.4001. JAMA Cardiol. 2017. PMID: 27851837 No abstract available.
• Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.

  Arihiro S, Todo K, Koga M, Furui E, Kinoshita N, Kimura K, Yamagami H, Terasaki T, Yoshimura S, Shiokawa Y, Kamiyama K, Takizawa S, Okuda S, Okada Y, Nagakane Y, Kameda T, Hasegawa Y, Shibuya S, Ito Y, Nakashima T, Takamatsu K, Nishiyama K, Matsuki T, Homma K, Takasugi J, Tokunaga K, Sato S, Kario K, Kitazono T, Toyoda K; SAMURAI Study Investigators. Arihiro S, et al. Int J Stroke. 2016 Jul;11(5):565-74. doi: 10.1177/1747493016632239. Epub 2016 Feb 29. Int J Stroke. 2016. PMID: 26927811
• Stroke prevention in atrial fibrillation – latest guideline recommendations and real world data.

  Johnson V, Schmitt J, Hamm CW. Johnson V, et al. Med Monatsschr Pharm. 2017 Apr;40(4):167-70. Med Monatsschr Pharm. 2017. PMID: 29952167 Review. English, German.
• 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.

  Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Ioachim PM, Tica O, Boriani G, Cimaglia P, Diemberger I, Hellum CF, Mortensen B, Maggioni AP. Lip GY, et al. Am J Med. 2014 Jun;127(6):519-29.e1. doi: 10.1016/j.amjmed.2013.12.022. Epub 2014 Jan 28. Am J Med. 2014. PMID: 24486284
• Cancer, atrial fibrillation, and stroke.

  Fitzpatrick T, Carrier M, Le Gal G. Fitzpatrick T, et al. Thromb Res. 2017 Jul;155:101-105. doi: 10.1016/j.thromres.2017.05.006. Epub 2017 May 9. Thromb Res. 2017. PMID: 28528288 Review.